Score |
Tenovil 4 μg/kg QD (n=22) |
Tenovil 8 μg/kg TIW (n=21) | Pooled Tenovil (n=43) | Pooled placebo (n=22) |
i0 | 11 (50%) | 9 (43%) | 20 (46%) | 10 (45%) |
i1+i2 | 3 (14%) | 11 (52%) | 14 (30%) | 9 (41%) |
i3+i4 | 2 (9%) | 1 (5%) | 3 (9%) | 2 (9%) |
Missing | 6 (27%)2-150 | — | 6 (14%)2-150 | 1 (5%)2-151 |
↵2-150 These subjects did not have a rating at treatment end point for the following reasons: two subjects did not meet protocol eligibility; two subjects experienced an adverse event; one subject had an anatomical problem with regard to endoscopy; and one subject did not wish to continue the study.
↵2-151 One subject experienced an adverse event during randomisation and did not receive the study medication.